Tidutamab (Anti-CD3 & SSTR2) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). It can be used in neuroendocrine tumors (NETs) and small cell lung cancer (SCLC). MW :147.36 KD.